The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis

Michael Sadek, MD1, Omer Iqbal, MD2, Fakiha Siddiqui, BDS2, Sean Till, MD1, Melissa Mazariegos, BS1, Edward Campbell, PhD3, Kumaran Mudaliar, MD4, Jodi Speiser, MD4, Emily Bontekoe, BS2, Ahmed Kouta, RPH2, Ambar Farooqui, MD2, Bharathi Daravath, MD2, Dalia Qneibi, MD2, Ramy Sadek, MD5, Debra Hoppensteadt, PhD2, Jawed Fareed, PhD2, and Charles Bouchard, MD6

Abstract
Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are Severe Cutaneous Adverse Reactions (SCARS) characterized by fever and mucocutaneous lesions leading to necrosis and sloughing of the epidermis. Conjunctival lesions are reported in 85% of patients. The pathogenesis of SJS/TEN/SCARS is not completely understood. It is hypothesized that IL-13, IL-15 and Granulysin expressed in plasma and skin may play a role. We measured the circulating levels of these cytokines in the plasma using ELISA and their expression in the skin using immunofluorescence microscopy. A total of 12 SJS/TEN skin biopsy samples (8 SJS, 2 SJS/TEN overlap and 2 TEN) were analyzed. Biopsy samples from patients with Lichen Planus (an inflammatory condition of the skin and mucous membranes) served as controls. Studies were also performed in human corneal epithelial cells where expression of these cytokines were measured following a challenge with TNF-α (0, 1, 10 and 100 ng/ml). The intensity of immunofluorescence was measured using Imaris® software. The results showed significantly increased expression of these cytokines in the skin biopsy samples as measured by the average intensities of IL-13 (6.1 x 133.0 ± 4.231 x 10^8) and Granulysin (4.2 x 123.0 ± 1.62 x 10^5) compared to Lichen planus control (3.0 x 123.0 ± 1.62 x 10^5). Increased expression of IL-13 and IL-15 were noted in cell culture studies and in the plasma samples when compared to Normal Human Plasma as controls. It is concluded that IL-13, IL-15 and Granulysin play a role in the pathogenesis of SJS/TEN.

Keywords
Stevens-Johnson syndrome, toxic epidermal necrolysis, granulysin, IL13, IL-15, immunofluorescence microscopy

Introduction
Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare life-threatening Severe Cutaneous Adverse Reactions (SCARS) with an estimated incidence ranging from 2 to 7 cases per million people per year. Other examples of SCARS include Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome) and Acute Generalized Exanthematous Pustulosis (AGEP). The SJS was first described in 1922, when the American pediatricians Albert Mason Stevens and Frank Chambliss Johnson reported the cases of 2 boys aged 7 and 8-year-old with “an extraordinary, generalized eruption with continued fever, inflamed buccal mucosa, and severe purulent conjunctivitis.” SJS and TEN are most often drug-induced,  

1 Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA
2 Cardiovascular Research Institute, Loyola University Chicago, Health Sciences Division, Maywood, IL, USA
3 Department of Microbiology and Immunology, Loyola University Medical Center, Maywood, IL, USA
4 Department of Pathology, Loyola University Medical Center, Maywood, IL, USA
5 Department of Medicine, University of California Los Angeles, Olive View, Maywood, IL, USA
6 Department of Ophthalmology, Loyola University Medical Center, Maywood, IL, USA

Corresponding Author:
Michael Sadek, MD, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.
Email: michaelbsadek@gmail.com
characterized by fever and mucocutaneous lesions resulting in necrosis and sloughing of the epidermis. SJS and TEN are distinguished based on the severity and involvement of the body surface area. SJS is less severe and the skin sloughing is less than 10% of the body surface (BSA). TEN is more severe and the sloughing is more than 30% of BSA. When the involvement is greater than 10% but less than 30% of the body surface, it is referred to as SJS/TEN overlap syndrome. SJS and TEN are immune-mediated reactions, considered to be T-cell mediated, characterized by a painful blisters rash often associated with multiorgan involvement and commonly fever, hematologic abnormalities, ophthalmologic and genitourinary involvement. Drugs are the leading cause of SJS and TEN in children. However, in addition to the drugs, infections particularly Mycoplasma pneumoniae and herpes viruses are associated with greater proportions of pediatric population. A wide variety of over 200 different drugs are implicated in its pathogenesis. Some of the most common culprit drugs include anti-gout agents, antibiotics, anti-psychotic and antiepileptics, and non-steroidal anti-inflammatory drugs (NSAIDS). The drug exposure generally precedes the onset of symptoms by 1 to 3 weeks. Signs and symptoms such as confluent erythema, facial edema, skin rash, palpable purpura, skin necrosis, blister with or without epidermal detachment, mucous membrane erosions and crusting and swelling of tongue should usually alert the physician. Several strong associations of prevalence of SJS/TEN in Southeast Asia have been documented with associations of HLA-A*0206, HLA-B*44:03, HLA-B*1502 (carbamazepine) and HLA-B*5801 (allopurinol) genotypes. In the United States, 10% of the total 12 million people, self-identified as Asian in the 2000 census are positive for HLA-B*1502 and its association with carbamazepine-induced SJS/TEN. Owing to the data implicating the HLA-B*1502 as a marker for carbamazepine-induced SJS/TEN in Han Chinese but not in Caucasian patients, the FDA recommends genotyping all Asians for the pathogenesis of SJS/TEN as potential biomarkers for disease severity. Interleukin-15 was found to be associated with severity and mortality in SJS/TEN. This study is designed to better understand the roles of IL-13, IL-15 and Granulysin in the pathogenesis of SJS/TEN. It is hypothesized that IL-13, IL-15 and Granulysin have crucial roles in the pathogenesis of SJS/TEN.

Materials & Methods

The study is designed to study a) The corneal sample study- the histopathological staining of archived skin biopsy slides of patients with SJS/TEN, b) plasma samples study of patients with SJS/TEN and c) cell culture study using human corneal epithelial cells. The plasma samples of patients with SJS/TEN were obtained from a recent prospective study, however, the corneal biopsy slides are from patient samples which are archived in the pathology department of Loyola University Medical Center, after the patients had undergone corneal transplantation. Hence, the plasma samples and archived corneal biopsy samples may be from different patients with SJS/TEN. In this study we highlight the immunofluorescent staining of the corneal biopsy slides.

Immunofluorescence Microscopy of Skin Biopsy Samples

Under a current Loyola institutional review board (IRB) protocol, a total of 12 SJS/TEN skin biopsy samples (8 SJS, 2 SJS/TEN overlap and 2 TEN) were analyzed. Due to the limitations of our IRB protocol, we were unable to obtain skin biopsy and plasma samples from the same patient. Biopsy samples from patients with Lichen Planus (an inflammatory condition of the skin and mucous membranes) served as controls. These paraffin embedded skin samples were obtained from the Loyola University Medical Center core pathology lab archives. All tissue samples were de-identified. The pathologists participating in this study maintained a list of pertinent personal health information (PHI) tied to these samples. All samples were sectioned using an American Optical model 820 micrometre at 4 microns thick and placed on positively charged glass slides. All slides were stored and processed in the same manner. Slides were first deparaffinized by washing 3 times with xylene for 5 minutes each. The slides were then rehydrated using a progressive ethanol gradient. They were washed twice in 100% ethanol (EtOH) for 2 minutes, once in 95% EtOH for 5 minutes, and once in 70% ethanol for 5 minutes. Slides were then rinsed with distilled water for 1 minute and washed for 5 minutes in a phosphate buffer solution (PBS). All slides were blocked using 10% normal donkey serum (NDS) with 0.01% sodium azide for 1 hour. Slides were then treated with either...
IL-13 primary antibody (1:100; R&D systems, Minneapolis, MN) or Granulysin primary antibody (1:200; PeproTech, Rocky Hill, NJ) and incubated overnight in a humidified dark box at 4 degrees Celsius. Following incubation, the biopsies were washed 3 times with PBS and incubated with secondary donkey anti goat IgG (Jackson Immuno Research, West Grove, PA) fluorescein isothiocyanate (FITC), and 4',6'-diamindino-2 phenylindole (DAPI) stain for 30 minutes. After washing with PBS, slide covers were mounted with fluorogel. For each slide stained with primary antibody, an additional control slide was prepared. These control slides were incubated with 10% NDS instead of IL-13 or Granulysin primary antibody and stained with secondary donkey anti goat IgG, FITC, and DAPI antibodies. These control slides were utilized to determine the level of background auto-fluorescence in all tissue samples. Deconvolution immunofluorescence (IF) was performed on all slides using a DeltaVision microscope equipped with a digital camera. Exposure times and settings were kept constant for all samples. After imaging, fluorescent intensity sum per punctum was determined using Imaris® software. Following the subtraction of background auto-fluorescence fluorescence from all samples, the degree of IF above baseline was quantified using the surface function in the 488-nm channel (FITC stained IL-13 or Granulysin). Statistical analysis was performed using Graph Pad Prism software. Seen below sample images depicting how Imaris® was used to quantify data (Figure 1).

Figure 1. A1-A4 shows expression of IL-13 in SJS Patients. B1-B4 shows expression of Granulysin in SJS patients. C1-C4 shows expression of IL-13 in TEN patients. D1-D4 shows expression of IL-13 and Granulysin in LP patients.

IL-13 primary antibody (1:100; R&D systems, Minneapolis, MN) or Granulysin primary antibody (1:200; PeproTech, Rocky Hill, NJ) and incubated overnight in a humidified dark box at 4 degrees Celsius. Following incubation, the biopsies were washed 3 times with PBS and incubated with secondary donkey anti goat IgG (Jackson Immuno Research, West Grove, PA) fluorescein isothiocyanate (FITC), and 4',6'-diamindino-2 phenylindole (DAPI) stain for 30 minutes. After washing with PBS, slide covers were mounted with fluorogel. For each slide stained with primary antibody, an additional control slide was prepared. These control slides were incubated with 10% NDS instead of IL-13 or Granulysin primary antibody and stained with secondary donkey anti goat IgG, FITC, and DAPI antibodies. These control slides were utilized to determine the level of background auto-fluorescence in all tissue samples. Deconvolution immunofluorescence (IF) was performed on all slides using a DeltaVision microscope equipped with a digital camera. Exposure times and settings were kept constant for all samples. After imaging, fluorescent intensity sum per punctum was determined using Imaris® software. Following the subtraction of background auto-fluorescence fluorescence from all samples, the degree of IF above baseline was quantified using the surface function in the 488-nm channel (FITC stained IL-13 or Granulysin). Statistical analysis was performed using Graph Pad Prism software. Seen below sample images depicting how Imaris® was used to quantify data (Figure 1).

Twenty paraffin embedded unstained slides of skin from biopsy confirmed Lichen planus (LP) patients (4 slides per patient) were used as a positive control group. These slides were prepared and analyzed using the methodology described above. For each LP skin sample, a second slide was also prepared without granulysin or IL-13 antibody to determine the level of auto-fluorescence in each sample. Of note, these skin biopsy and plasma samples are not always obtained from the same patient.
Cell Culture Study

Human Corneal Epithelial Cell Cultures were maintained. The human corneal epithelial cells were grown to confluency and were challenged with different concentrations of TNF-α ranging from 0, 1, 10, 100 ng/ml. Then the cells were plated and challenged with plasma from patients with Stevens Johnson Syndrome and toxic epidermal necrolysis. Following incubation, the supernatants were collected, and the cells stained with IL-13 and Granulysin antibodies and immunofluorescence was determined. The collected supernatants were aliquoted and stored at -70°C freezer. The samples were later thawed together with SJS/TEN patient plasma samples and the quantification of IL-13, Granulysin and IL-15 analyzed by ELISA.

Plasma Samples

The de-identified and discarded plasma samples from patients with SJS/TEN were obtained from the Loyola University core labs. Under a current, Loyola IRB protocol, a total of 76 de-identified platelet-poor plasma samples from the Loyola core pathology lab (12 patients) with a diagnosis of SJS, SJS/TEN overlap or TEN were analyzed using ELISA. One patient (2 plasma samples) was excluded from analysis due to confirmed final surgical pathology diagnosis that was negative for SJS, SJS/TEN overlap or TEN. All plasma samples were stored at -70°C and contained either EDTA or citrate as an anticoagulant. Normal human plasma and pathologic pooled plasma were used as negative controls. ELISA analysis of plasma samples was performed using a Quantitative Human IL-13 kit (Abcam, Cambridge, UK) and a Quantitative Human Granulysin kit (Abcam, Cambridge, UK). All reagent preparation and ELISA experimentation was preformed according to the manufacturer’s instructions. The Quantikine Human IL-13 Immunoassay is a 4.5-hour solid phase ELISA designed to measure IL-13 levels in cell culture supernates, serum, and plasma. It contains E. coli-expressed recombinant human IL-13 and antibodies raised against the recombinant factor. This immunoassay has been shown to quantitate recombinant human IL-13 accurately. Results obtained using natural human IL-13 showed dose response curves that were parallel to the standard curves obtained using the recombinant kit standards. These results indicate that this kit can be used to determine relative mass values for natural human IL-13. Both IL-13 and IL-15 plates were analyzed on a SpectraMax plus 384 microplate reader (Molecular Devices, Sunnyvale, CA) set at 450 nm. Statistical analysis was performed using Graph Pad Prism software.

Results

The results presented reflect the 3 aspects of the study a) Immunofluorescence study, b) Cell culture study and c) Plasma cell study.

a): Immunofluorescence study:

IL-13 Intensities in SJS/TEN and Lichen Planus Tissue Samples

A total 12 SJS/TEN (8 SJS, 2 SJS/TEN overlap and 2 TEN) and 5 LP biopsy samples were analyzed. All puncta for SJS/TEN patients above background auto-fluorescent intensity were pooled (N = 12, 1600 sample points) and compared against pooled LP puncta (N = 8, 1300 sample points) using a Mann-Whitney test. There was a significantly increased expression of IL-13 (p = 0.00001) in the epithelium of pooled SJS, SJS/TEN overlap or TEN patients (average IF intensity of 6.1 x 133.0 ± 4.231 x 10^8 compared to the epithelium of pooled LP patients (average IF intensity of 3.0 x 111.0 ± 1.73 x 110.0 (p < 0.00001) (Figure 1).
Granulysin Intensities in SJS/TEN and Lichen Planus Tissue Samples

A total of 12 SJS/TEN (8 SJS, 2 SJS/TEN overlap and 2 TEN) and 5 LP biopsy samples were analyzed. All puncta for SJS/TEN patients above background auto-fluorescent intensity were pooled (N = 12, 1600 sample points) and compared against pooled LP puncta (N = 8, 1600 sample points) using a Mann-Whitney test. There was a significantly increased expression of Granulysin (p = 0.00003) in the epithelium of pooled SJS, SJS/TEN overlap or TEN patients (average IF intensity of 4.2 ± 8.426 x 10^8 compared to the epithelium of pooled LP patients (average IF intensity of 3.0 x 111.0 ± 1.62 x 10^8 (p < 0.00001) (Figure 1).

Granulysin Intensities in SJS/TEN and Lichen Planus Tissue Samples

A total of 12 SJS/TEN (8 SJS, 2 SJS/TEN overlap and 2 TEN) and 5 LP biopsy samples were analyzed. All puncta for SJS/TEN patients above background auto-fluorescent intensity were pooled (N = 12, 1600 sample points) and compared against pooled LP puncta (N = 8, 1600 sample points) using a Mann-Whitney test. There was a significantly increased expression of Granulysin (p = 0.00003) in the epithelium of pooled SJS, SJS/TEN overlap or TEN patients (average IF intensity of 4.2 ± 8.426 x 10^8 compared to the epithelium of pooled LP patients (average IF intensity of 3.0 x 111.0 ± 1.62 x 10^8 (p < 0.00001) (Figure 1).
Expression of IL-13 and Granulysin Following a TNF-\(\alpha\) Challenge in Human Corneal Epithelial Cell Cultures

The cells were studied for the expression of IL-13 and Granulysin using immunofluorescence microscopy. The intensities of immunofluorescence of IL-13 and Granulysin were calculated using Imaris® methodology (Figures 2 and 3).

c): Plasma Analysis:

IL-13 and IL-15 Expressions in plasma samples: All patients showed elevated average intensities (IL-13) compared to the normal human plasma (NHP) control \(P < 0.0001\) (Figure 4 and 5). All patients showed elevated average intensities of IL-15 as compared to the normal human plasma (NHP) control \(p < 0.0001\) (Figure 4, 5, and 6).

Discussion

In this study we investigated the roles of IL-13, IL-15 and Granulysin in the pathogenesis of SJS/TEN. The association of combined IL-13/IL-4 R signaling pathway gene polymorphism with Stevens Johnson Syndrome accompanied by ocular surface complications has already been reported earlier.\(^{21}\) The role of Granulysin in the pathogenesis of SJS/TEN was earlier reported.\(^{6,19}\) We studied the role of IL-13 and Granulysin in the pathogenesis of SJS/TEN in terms of their expression as studied by immunofluorescence microscopy and their quantitative determination using ELISA technique.

The immunofluorescence microscopy study: There was a significantly increased expression of Granulysin (\(p = 0.00003\)) in the epithelium of pooled SJS, SJS/TEN overlap or TEN patients (average IF intensity of \(4.2 \times 123.0 \pm 8.426.0 \times 10^8\), compared to the epithelium of pooled LP patients (average IF intensity of \(3.0 \times 111.0 \pm 1.62 \times 10^8\) (\(p < 0.00001\)). The increased expression of IL-13 and Granulysin suggests that these cytokines have a role in the pathogenesis of SJS/TEN.

Cell Culture Study: Given that TNF-\(\alpha\) levels are increased in patients with SJS/TEN,\(^{24}\) we stimulated the cultured human corneal epithelial cells with TNF-\(\alpha\) at different concentrations ranging from 0, 1, 10 and 100 ng/ml and studied the expression of IL-13 and Granulysin using anti-IL-13 antibody and anti-Granulysin antibody. As seen in Figure 2 there was a concentration-dependent response with TNF-\(\alpha\)-induced expression of IL-13 and Granulysin. Our findings related to TNF-\(\alpha\)-induced expression of IL-13 and Granulysin by cultured human corneal epithelial cells is a first reported finding. TNF-\(\alpha\)-induced expression of IL-13 and Granulysin in human corneal epithelial cell culture serves as a model to study the expression of other cytokines involved in the pathogenesis of SJS/TEN. Further studies are ongoing in our labs to study the TNF-\(\alpha\)-induced expression of other cytokines using human corneal epithelial cells cultures.

Plasma Study: All patients studied showed elevated average levels of IL-13 and IL-15 compared to the normal human plasma (NHP) control (\(p < 0.0001\)). The plasma levels of Granulysin by ELISA were not performed in this study since its increased levels have been reported earlier.\(^{6,19}\) IL-13 also plays a key role in the pathogenesis of allergy, cancer, and tissue fibrosis. Similarly, IL-15 is a proinflammatory cytokine. IL-15 binds to its receptor complex and activates an immune response through a signaling cascade in natural killer cells and subsets of T cells.\(^{25}\) IL-15 is associated with severity and mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.\(^{23}\) Understanding of the roles of IL-13, IL-15 and Granulysin in the pathogenesis of SJS/TEN is crucial in harnessing the adverse effects associated with this condition in order to formulate better treatment strategies. It is also important to identify other cytokines which might be playing a role in the pathogenesis of SJS/TEN such that the some of the adverse effects which cause long-term sequelae such as ocular sequelae may be prevented or better treated.

Figure 5. IL-13 and IL-15 ELISA analysis of SJS/TEN citrated plasma samples. A total of 76 plasma samples from 12 SJS/TEN patients were analyzed using Abcam Quantitative IL-13 and Quantitative IL-15 ELISA kits. Normal human plasma (George King Inc.) was used as a healthy control. Results reveal mildly elevated levels of IL-13 and IL-15 in the plasma of SJS/TEN patients compared to NHP. ANOVA and Dunnett’s multiple comparisons tests revealed statistical significance in IL-13 and IL-15 expression in all SJS plasma samples when compared to NHP control (George King Inc.).
**Conclusion**

Skin biopsy samples from patients with SJS/TEN showed increased expression of IL-13 and granulysin compared to Lichen planus controls. Plasma samples obtained from patients with SJS/TEN also showed increased expression of IL-13 and IL-15 as determined by ELISA assays. IL-13, IL-15 and granulysin play a role in the pathogenesis of SJS/TEN. Increased expression of IL-13 and granulysin were noted when cultured human corneal epithelial cells were challenged with TNF-z and studies using immunofluorescence microscopy.

**Acknowledgments:**

The author of this paper would like to acknowledge research funding from the Illinois Society for the Prevention of Blindness (ISPB) and the Perritt Charitable Foundation. We would also like to acknowledge Dr. Campbell of the Department of Microbiology and Immunology and the faculty members of the Hemostasis and Thrombosis laboratories for their assistance and guidance throughout this project. We also would like to thank Dr. Omer Iqbal and Dr. Charles Bouchard who served as mentors.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**ORCID iDs**

Michael Sadek https://orcid.org/0000-0003-0110-2239  
Fakiha Siddiqui https://orcid.org/0000-0002-2219-7049  
Ahmed Kouta https://orcid.org/0000-0001-7579-9572  
Debra Hoppensteadt https://orcid.org/0000-0001-9342-4213  
Jawed Fareed https://orcid.org/0000-0003-3465-2499

**References**

1. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of toxic epidermal necrolysis, Stevens Johnson Syndrome, and erythema multiforme. *Arch Dermatol*. 1993;129(1):92-96.
2. Stevens A, Johnson F. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. *Am J Child*. 1922;24:526-533.
3. White KD, Abe R, Arden-Jones M, et al. SJS/TEN 2017: building multidisciplinary networks to drive science and translations. *J Allergy Clin Immunol Pract*. 2018;3(1):38-69.
4. Leaute-Labreze C, Lamireau T, Chawki D, Maleville J, Tateb A. Diagnosis, classification, and management of erythema multiforme and Stevens-Johnson Syndrome. *Arch Dis Child*. 2000;83(4):347.
5. Wetter DA, Camilleri MJ. Clinical, etiologic and histopathologic features of Stevens-Johnson Syndrome during an 8-year period at Mayo Clinic. *Mayo Clin Proc*. 2010;85(2):131.
6. Schlop E, Stuhmer A, Rzany B, Victor N, Zenigraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome. An epidemiologic study from East Germany. *Arch Dermatol*. 1991;127(6):839-842.
7. Mockenhaupt M, Kelly JP, Kaufman D, Stern RS; SCAR Study Group. The risk of Stevens-Johnson Syndrome and toxic epidermal necrolysis associated with non-steroidal anti-inflammatory drugs: a multinational perspective. *J Rheumatol*. 2003;30(10):2234.
8. Devi K, George S, Criton S, Suja V, Srivedi PK. Carbamazepine–the commonest cause of toxic epidermal necrolysis and Stevens-
Johnson Syndrome: a study of 7 years. *Indian J Dermatol Venereol Leprol.* 2005;71(5):325.

9. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson Syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study. *J Invest Dermatol.* 2008;128(10):35.

10. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. *N Engl J Med.* 2006;331(19):1272-1285.

11. Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revaz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. *Arch Dermatol.* 1987;123(9):1171-1173.

12. Chung WH, Hung SI, Hong GS, et al. Medical genetics: a marker for Stevens-Johnson Syndrome. *Nature.* 2004;428(6982):486.

13. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. *Proc Natl Acad Sci USA.* 2005;102(11):4234-4239.

14. Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. *Pharmacogenet Genomics.* 2006;16(4):297-306.

15. Ferrell PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: USFDA recommendations. *Pharmacogenomics.* 2008;9(10):1543-1546. doi:10.2217/14622416.9.10.1543

16. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. *N Engl J Med.* 1994;331(19):1272-1285.

17. Roujeau JC. Immune mechanisms in drug allergy. *Allergol Int.* 2006;55(1):27-33.

18. Nassif A, Bensussan A, Boumsell L, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. *J Allergy Clin Immunol.* 2004;114(5):1209-1215.

19. Quinn AM, Brown K, Bonish BK, et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. *Arch Dermatol.* 2005;141(6):683-687.

20. Nassif A, Bensussan A, Dorothée G, et al. Drug-specific cytotoxic T cells in the skin lesions of a patient with toxic epidermal necrolysis. *J Invest Dermatol.* 2002;118(4):728-733.

21. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. *Science.* 1998;282(5388):490-493.

22. Pereira FA, Mudgil AV, Rosmarin DM. Toxic epidermal necrolysis. *J Am Acad Dermatol.* 2007;58:181-200.

23. Stur K, Karhofer FM, Stingle G. Soluble Fas ligand: a discriminative feature between drug-induced skin eruptions and viral exanthemas. *J Invest Dermatol.* 2007;127(4):802-807.

24. Bronnimann M, Yawalkar N. Histopathology of drug-induced exanthems: Is there a role in diagnosis of drug allergy? *Curr Opin Allergy Clin Immunol.* 2005;5(4):317-321.

25. Chave TA, Mortimer NJ, Sladden MJ, et al. Toxic epidermal necrolysis: current evidence, practical management and future directions. *Br J Dermatol.* 2005;153(2):241-253.

26. Chung W-H, Hung S-I, Yung J-Y, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. *Nat Med.* 2008;14(12):1343-1350.

27. Vern AK, Walenga JM, Hoppensteadt D, Gamelli R. Patients with Stevens-Johnson syndrome and toxic epidermal necrolysis develop coagulopathies similar to those seen in burn patients: A pilot study. *Int J Clin Exp Dermatol.* 2018;3(1):1-9.

28. Ueta M, Sotozono C, Inatomi T, Kojima K, Hamuro J, Kinoshita S. Association of combined IL-13/IL-4 R signaling pathway gene polymorphism with Stevens-Johnson syndrome accompanied by ocular surface complications. *Invest Ophthalmol Vis Sci.* 2008;49(5):1809-1813.

29. Till SD, Iqbal O, Dharan A, et al. The roles of IL-33 and TGF-β1 in the pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis: potential biomarkers for disease severity. *J Ophthalmol Eye Care.* 2018;1(1):105.

30. Su S-C, Mockenhaupt M, Wolkerstein P, et al. Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. *J Invest Dermatol.* 2017;137(5):1065-1073.